Dapagliflozin Influences Ventricular Hemodynamics and Exercise-Induced Pulmonary Hypertension in Type 2 Diabetes Patients ― A Randomized Controlled Trial ―
Hiroyuki Kayano, Shinji Koba, Tsutomu Hirano, Taiju Matsui, Hiroto Fukuoka, Hiroaki Tsuijita, Shigeto Tsukamoto, Toshiyuki Hayashi, Tsutomu Toshida, Norikazu Watanabe, Yuji Hamazaki, Eiichi Geshi, Mikitaka Murakami, Kazuo Aihara, Koujin Kaneko, Hirokazu Yamada, Youichi Kobayashi, Toshiro Shinke
Abstract
BACKGROUND: This prospective randomized multicenter open-label trial evaluated whether sodium-glucose cotransporter-2 inhibitor (SGLT2-i) improves left ventricular (LV) pump function and suppresses elevation of LV filling pressure (LVFP) and right ventricular systolic pressure (RVSP) during exercise in type 2 diabetes mellitus (T2DM) patients. METHODS AND RESULTS: ). Both RVSP and LVFP during exercise significantly decreased from baseline to 6 months after starting treatment in the D-group (P<0.001). No changes to either parameter was observed in the C-group. The SVi and CI did not improve in either group. Both home and office blood pressure significantly decreased in the D-group. Decreases in HbA1c were somewhat greater in the C-group. CONCLUSIONS: Dapagliflozin significantly improved RVSP and LVFP during exercise in patients with T2DM and cardiovascular risk, which may contribute to favorable effects on heart failure.